Business
Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA® (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting
Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2] ZYMFENTRA® is
By: en_prnasisa
- Oct 30 2024
- 0
- 0 Views
Share this page
Guest Posts by Easy Branches at the American College of Gastroenterology 2024 Annual Scientific Meeting&url=https://easybranches.com/feed/hk/business/10601572&media=https://easybranches.com/feed/uploads/2024/10/4176f3858c0d27c3da43fb2e9e326aa5.jpg){kind=link}
